ArticleBreast cancer research : BCR2024

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.

Stephen G Smoots et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.